A new narrative review looked at how aging liver cells, called senescent hepatocytes, might contribute to metabolic dysfunction-associated steatotic liver disease, or MASLD. The review gathered evidence from human, animal, and laboratory studies. It found that these aging cells build up in both experimental models and human MASLD. Once present, they can send signals that affect other liver cells, including immune cells and cells that form scar tissue. This may lead to inflammation and fibrosis, which is scarring of the liver.
The review suggests that when the immune system works well, these aging cells may be cleared away and even help remove damaged cells. But in a liver that is chronically injured, the immune system may not clear them effectively. Then, continued production of these cells and their signals may promote inflammation and scarring.
However, the review has important limitations. There are no universal markers to identify senescent cells, and direct evidence in humans is limited. The effects of senescence appear to depend on context, immune function, and how long the injury lasts. The review describes senescence as a plausible contributor to MASLD progression, not a proven cause.
There are no safety findings reported because this is not a clinical trial. The main takeaway is that targeting senescent cells is an area of research, but it is not yet ready for clinical use. People with MASLD should talk to their doctor about proven treatments and lifestyle changes.
